ICH
MCID: HMR039
MIFTS: 57

Hemorrhage, Intracerebral (ICH)

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Hemorrhage, Intracerebral

MalaCards integrated aliases for Hemorrhage, Intracerebral:

Name: Hemorrhage, Intracerebral 56 37
Hemorrhage, Intracerebral, Susceptibility to 56 29 13 6 39
Intracerebral Hemorrhage 73 54 17
Hemorrhagic Stroke 73 54 42
Ich 56 74 73
Stroke, Hemorrhagic, Susceptibility to 56 6
Stroke, Hemorrhagic 56
Cerebral Hemorrhage 43
Brain Hemorrhage 71

Classifications:



External Ids:

OMIM 56 614519
MeSH 43 D002543
UMLS 71 C0553692

Summaries for Hemorrhage, Intracerebral

MedlinePlus : 42 A stroke is a medical emergency. There are two types - ischemic and hemorrhagic. Hemorrhagic stroke is the less common type. It happens when a blood vessel breaks and bleeds into the brain. Within minutes, brain cells begin to die. Causes include a bleeding aneurysm, an arteriovenous malformation (AVM), or an artery wall that breaks open. Symptoms of stroke are Sudden numbness or weakness of the face, arm or leg (especially on one side of the body) Sudden confusion, trouble speaking or understanding speech Sudden trouble seeing in one or both eyes Sudden trouble walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause It is important to treat strokes as quickly as possible. With a hemorrhagic stroke, the first steps are to find the cause of bleeding in the brain and then control it. Surgery may be needed. Post-stroke rehabilitation can help people overcome disabilities caused by stroke damage. National Institute of Neurological Disorders and Stroke

MalaCards based summary : Hemorrhage, Intracerebral, also known as hemorrhage, intracerebral, susceptibility to, is related to porencephaly and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Hemorrhage, Intracerebral is COL4A1 (Collagen Type IV Alpha 1 Chain), and among its related pathways/superpathways are Folate Metabolism and Microglia Activation During Neuroinflammation: Overview. The drugs Heparin and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

UniProtKB/Swiss-Prot : 73 Intracerebral hemorrhage: A pathological condition characterized by bleeding into one or both cerebral hemispheres including the basal ganglia and the cerebral cortex. It is often associated with hypertension and craniocerebral trauma. Intracerebral bleeding is a common cause of stroke.

Wikipedia : 74 Intracerebral hemorrhage (ICH), also known as cerebral bleed, is a type of intracranial bleed that... more...

More information from OMIM: 614519

Related Diseases for Hemorrhage, Intracerebral

Diseases related to Hemorrhage, Intracerebral via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 839)
# Related Disease Score Top Affiliating Genes
1 porencephaly 33.0 COL4A2 COL4A1
2 stroke, ischemic 31.5 PLAT CST3 APOE ACE
3 intracranial embolism 30.3 PLAT ACE
4 hypercholesterolemia, familial, 1 30.2 APOE ACE
5 familial porencephaly 30.2 COL4A2 COL4A1
6 angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps 30.1 COL4A2 COL4A1
7 col4a1-related familial vascular leukoencephalopathy 30.1 COL4A2 COL4A1
8 ischemia 30.0 PLAT APP ACE
9 acute myocardial infarction 30.0 PLAT CST3 ACE
10 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 30.0 COL4A1 APP APOE
11 intracranial aneurysm 30.0 PLAT APOE ACE
12 hypertensive nephropathy 29.9 CST3 ACE
13 arteriolosclerosis 29.8 APP APOE
14 anuria 29.8 CST3 ACE
15 hereditary cerebral amyloid angiopathy 29.8 CST3 APP
16 arteriosclerosis 29.8 CST3 APOE ACE
17 communicating hydrocephalus 29.7 APP APOE
18 cardiac tamponade 29.7 PLAT ACE
19 normal pressure hydrocephalus 29.7 APP APOE ACE
20 amyloidosis 29.6 CST3 APP APOE
21 cerebral atherosclerosis 29.6 APOE ACE
22 atherosclerosis susceptibility 29.6 PLAT APOE ACE
23 coronary heart disease 1 29.5 PLAT APOE ACE
24 peripheral artery disease 29.5 ACE CST3 APOE
25 cardiac arrest 29.5 APP APOE ACE
26 amnestic disorder 29.5 APP APOE
27 cerebral amyloid angiopathy, app-related 29.5 CST3 APP APOE
28 apnea, obstructive sleep 29.4 APOE ACE
29 arteries, anomalies of 29.3 PLAT APOE ACE
30 dementia 29.3 CST3 APP APOE ACE
31 kidney disease 29.1 GSR CST3 COL4A1 APOE ACE
32 aphasia 29.1 PLAT APP APOE
33 chronic kidney disease 29.1 CST3 APOE ACE
34 speech and communication disorders 29.1 PLAT APP APOE
35 aortic aneurysm, familial abdominal, 1 29.1 CST3 APOE ACE
36 cerebral amyloid angiopathy, cst3-related 29.1 CST3 APP APOE
37 cerebral degeneration 29.1 COL4A1 APP APOE
38 vascular dementia 29.0 CST3 APP APOE ACE
39 vascular disease 28.9 PLAT CST3 CCM2 APOE ACE
40 cerebrovascular disease 28.9 PLAT COL4A1 APP APOE ACE
41 cataract 28.9 GSR COL4A1 APOE ACE
42 creutzfeldt-jakob disease 28.8 CST3 APP APOE
43 cardiovascular system disease 28.8 PLAT CST3 APOE ACE
44 myocardial infarction 28.7 PLAT GSR CST3 APOE ACE
45 hydrocephalus 28.7 PLAT APP APOE ACE
46 alzheimer disease 28.7 GSR CST3 APP APOE ACE
47 heart disease 28.1 PLAT GSR CST3 APOE ACE
48 hypertension, essential 28.1 PLAT GSR CST3 APOE ACE
49 diabetes mellitus, noninsulin-dependent 27.4 PLAT GSR CST3 APP APOE ACE
50 cerebral cavernous malformation, familial 11.8

Graphical network of the top 20 diseases related to Hemorrhage, Intracerebral:



Diseases related to Hemorrhage, Intracerebral

Symptoms & Phenotypes for Hemorrhage, Intracerebral

Clinical features from OMIM:

614519

UMLS symptoms related to Hemorrhage, Intracerebral:


seizures, tremor, angina pectoris, edema, chest pain, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Hemorrhage, Intracerebral:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 ACE APOE APP CCM2 COL4A1 COL4A2
2 homeostasis/metabolism MP:0005376 10.01 ACE APOE APP CCM2 COL4A1 COL4A2
3 hematopoietic system MP:0005397 9.98 ACE APOE APP CCM2 COL4A1 COL4A2
4 mortality/aging MP:0010768 9.92 ACE APOE APP CCM2 COL4A1 COL4A2
5 immune system MP:0005387 9.91 ACE APOE APP CCM2 COL4A1 COL4A2
6 muscle MP:0005369 9.8 APOE APP CCM2 COL4A1 COL4A2 CST3
7 nervous system MP:0003631 9.7 APOE APP CCM2 COL4A1 COL4A2 CST3
8 reproductive system MP:0005389 9.5 ACE APOE APP COL4A1 COL4A2 CST3
9 vision/eye MP:0005391 9.1 APOE CCM2 COL4A1 COL4A2 GSR PLAT

Drugs & Therapeutics for Hemorrhage, Intracerebral

Drugs for Hemorrhage, Intracerebral (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 353)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
2
Enoxaparin Approved Phase 4 9005-49-6 772
3
Dalteparin Approved Phase 4 9005-49-6
4
Probucol Approved, Investigational Phase 4 23288-49-5 4912
5
Nadroparin Approved, Investigational Phase 4
6
Simvastatin Approved Phase 4 79902-63-9 54454
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
9
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
10
Ezetimibe Approved Phase 4 163222-33-1 150311
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Insulin glargine Approved Phase 4 160337-95-1
13
Tirofiban Approved Phase 4 144494-65-5 60947
14
Atorvastatin Approved Phase 4 134523-00-5 60823
15
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
16
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
17
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
20
Nifedipine Approved Phase 4 21829-25-4 4485
21
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
22
Labetalol Approved Phase 4 36894-69-6 3869
23
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
24
tannic acid Approved Phase 4 1401-55-4
25
Acetaminophen Approved Phase 4 103-90-2 1983
26
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
27
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
28
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
29
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
30
Ibuprofen Approved Phase 4 15687-27-1 3672
31
Zinc Approved, Investigational Phase 4 7440-66-6 32051
32
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
33 Indobufen Investigational Phase 4 63610-08-2
34 Rosuvastatin Calcium Phase 4 147098-20-2
35 calcium heparin Phase 4
36 Heparin, Low-Molecular-Weight Phase 4
37 Anticholesteremic Agents Phase 4
38 Hypolipidemic Agents Phase 4
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40 Antimetabolites Phase 4
41 Lipid Regulating Agents Phase 4
42 Tranquilizing Agents Phase 4
43 Psychotropic Drugs Phase 4
44 Purinergic P2Y Receptor Antagonists Phase 4
45 Immunologic Factors Phase 4
46 Immunosuppressive Agents Phase 4
47 Antibiotics, Antitubercular Phase 4
48 Antifungal Agents Phase 4
49 GABA Agents Phase 4
50 Vasoconstrictor Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 558)
# Name Status NCT ID Phase Drugs
1 A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH) Unknown status NCT00699465 Phase 4 enoxaparin;enoxaparin placebo
2 Clinical Re-evaluation of Removing Blood Stasis Therapy of Herbal Medicine in Treating Acute Cerebral Hemorrhage Safety Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
3 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
4 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
5 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
6 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
7 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
8 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
9 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
10 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
11 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis Unknown status NCT00624091 Phase 4
12 Temperature Control in Central Fever in the Neuro-ICU Completed NCT00751634 Phase 4
13 Clinical Study on the Treatment of Hypertensive Cerebral Hemorrhage With Panax Notoginseng Saponins Completed NCT02999048 Phase 4 Panax Notoginseng Saponins
14 Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists Completed NCT00928915 Phase 4 Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
15 Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment? Completed NCT01115959 Phase 4 valproic acid;placebo bid
16 Model Study on the Comprehensive Treating Protocol and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine Completed NCT00548223 Phase 4 Dengzhan Shengmai capsule;placebo
17 Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke Completed NCT00966316 Phase 4 aspirin,chinese herbs;
18 The START Trial: Clinical Outcome in Acute Stroke Treatment After Imaging Guided Patient Selection for Interventional Revascularization Therapy Completed NCT00963989 Phase 4
19 Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial Completed NCT00125593 Phase 4 Simvastatin 20 mg;Ezetimibe 10mg;Placebo
20 Low-dose Versus Standard-dose Ateplase in Acute Ischemic Stroke ; A 4 Months Prospective Randomized Control Pilot Follow by Single Arm Standard Dose Ateplase Study. Completed NCT03847883 Phase 4 Intravenous Solution Ateplase
21 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
22 Establishment of Baseline and Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System Completed NCT00197392 Phase 4
23 Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery Completed NCT00190307 Phase 4 aspirin 75 mg/day
24 Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) Completed NCT00454662 Phase 4 olmesartan medoxomil / amlodipine or azelnidipine;olmesartan medoxomil / low dose thiazide type drug
25 Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial Completed NCT00846846 Phase 4
26 Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus Completed NCT00736515 Phase 4 Gliclazide MR and Insulin Glargine Injection;Biosynthetic Human Insulin Injection
27 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
28 Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty. Completed NCT00566891 Phase 4 tirofiban;Clopidogrel
29 Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification Completed NCT02225834 Phase 4 Atorvastatin
30 Study of Antithrombotic Treatment After IntraCerebral Haemorrhage Recruiting NCT03186729 Phase 4 Antithrombotic Agent
31 Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) for Blood Pressure Reduction in Patients With Primary Intracerebral Hemorrhage: A Randomized Controlled Trial Recruiting NCT03300479 Phase 4 Clevidipine;Urapidil
32 A Randomized, Exploratory, Open-label, Phase IV, Blinded Endpoint, Multicenter and Prospective Study to Evaluate the Effect of the Addition of Esmolol on the Current Therapeutic Regimen Used for the Treatment of Hemorrhagic Stroke Recruiting NCT03743103 Phase 4 Brevibloc, 10 Mg/mL Intravenous Solution;Nitroprusside, Sodium
33 A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke Recruiting NCT04200781 Phase 4 Granules of Shengdi Dahuang Decoction;Placebo
34 Clinical Study of Qingpeng Ointment in Treating Shoulder Syndrome During Rehabilitation Period of Cerebral Hemorrhage Recruiting NCT04039737 Phase 4 Qingpeng Ointment
35 Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial Recruiting NCT03772847 Phase 4 ginkgolide
36 Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial Recruiting NCT04148105 Phase 4 Cilostazol 100 MG
37 Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Recruiting NCT03595982 Phase 4 Procardia XL 30Mg;Procardia XL 60Mg
38 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
39 Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Not yet recruiting NCT03354026 Phase 4 AICH-PXZY;AICH-without PXZY;AICH-placebo
40 An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke Not yet recruiting NCT04143880 Phase 4 Progesterone
41 INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE Not yet recruiting NCT03871517 Phase 4 Indobufen;Aspirin
42 Outcome in Patients Treated With Intraarterial Thrombectomy - optiMAL Blood Pressure Control (OPTIMAL-BP) Not yet recruiting NCT04205305 Phase 4 conventional blood pressure control (labetalol, nicardipine);intensive blood pressure control (labetalol, nicardipine)
43 Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance Terminated NCT00289601 Phase 4 eptifibatide
44 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
45 BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents Terminated NCT00595647 Phase 4
46 Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage Terminated NCT01530880 Phase 4 Intravenous Ibuprofen;Acetaminophen (Standard of Care)
47 Does Maintenance of Normoglycemia Change Neurological Outcome in Patients Recovering From Traumatic Brain Injury and Subarachnoid or Intraparenchymal Hemorrhage? Terminated NCT01137773 Phase 4 Insulin;Conventional insulin treatment
48 The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial Withdrawn NCT01042574 Phase 4 Clevidipine butyrate
49 Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury Withdrawn NCT01526876 Phase 4 clevidipine butyrate
50 Pilot Study of Hypothermia for Intracerebral Hemorrhage in Croatia Unknown status NCT01221142 Phase 3

Search NIH Clinical Center for Hemorrhage, Intracerebral

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemorrhage, Intracerebral cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hemorrhage, Intracerebral:
GLP-1 CellBeads, encapsulated mesenchymal stem cells for intracerebral hemorrhage
Embryonic/Adult Cultured Cells Related to Hemorrhage, Intracerebral:
GLP-transfected mesenchymal stem cells PMIDs: 22985173 22034462

Cochrane evidence based reviews: cerebral hemorrhage

Genetic Tests for Hemorrhage, Intracerebral

Genetic tests related to Hemorrhage, Intracerebral:

# Genetic test Affiliating Genes
1 Hemorrhage, Intracerebral, Susceptibility to 29 ACE COL4A1 COL4A2

Anatomical Context for Hemorrhage, Intracerebral

MalaCards organs/tissues related to Hemorrhage, Intracerebral:

40
Brain, Heart, Liver, Kidney, Eye, Bone, Lung

Publications for Hemorrhage, Intracerebral

Articles related to Hemorrhage, Intracerebral:

(show top 50) (show all 304)
# Title Authors PMID Year
1
COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. 56 6
22522439 2012
2
COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. 56 6
22209247 2012
3
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 56 6
15277638 2004
4
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
5
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
6
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
7
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 6
15534175 2004
8
ACE1 polymorphism and progression of SARS. 6
15381116 2004
9
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
10
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
11
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
12
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
13
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
14
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
15
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 6
11687636 2001
16
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. 6
10841123 2000
17
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. 6
10643899 1999
18
A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population. 6
10636736 1999
19
The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. 6
10099885 1999
20
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. 6
9916793 1999
21
Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. 6
9737775 1998
22
ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. 6
9699903 1998
23
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 6
9259580 1997
24
D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. 6
9236417 1997
25
Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. 6
9120002 1997
26
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 6
8644984 1996
27
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 6
8541160 1995
28
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. 6
8675669 1995
29
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 6
7593601 1995
30
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. 6
7729604 1995
31
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 6
7854377 1995
32
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. 6
7909524 1994
33
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 6
8170965 1994
34
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. 6
8208911 1994
35
Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. 6
8314010 1994
36
Genetic associations with human longevity at the APOE and ACE loci. 6
8136829 1994
37
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 6
8131299 1993
38
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 6
8131300 1993
39
A potent genetic risk factor for restenosis. 6
8298638 1993
40
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 6
1328889 1992
41
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. 6
1386652 1992
42
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. 6
1319114 1992
43
PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). 6
1313972 1992
44
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. 6
1976655 1990
45
Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. 6
2849100 1988
46
Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. 6
2847529 1988
47
Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation. 61
31848737 2019
48
Gap Analysis Regarding Prognostication in Neurocritical Care: A Joint Statement from the German Neurocritical Care Society and the Neurocritical Care Society. 61
31368059 2019
49
The Full Outline of UnResponsiveness (FOUR) Score and Its Use in Outcome Prediction: A Scoping Systematic Review of the Adult Literature. 61
30411302 2019
50
Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A Systematic Review and Meta-analysis. 61
31081871 2019

Variations for Hemorrhage, Intracerebral

ClinVar genetic disease variations for Hemorrhage, Intracerebral:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382insertion risk factor 18061 17:61565892-61565893 17:63488531-63488532
2 COL4A1 NM_001845.6(COL4A1):c.1612C>G (p.Arg538Gly)SNV risk factor 39864 rs397514624 13:110839601-110839601 13:110187254-110187254
3 COL4A1 NM_001845.6(COL4A1):c.1588C>T (p.Pro530Ser)SNV Conflicting interpretations of pathogenicity 195868 rs145172612 13:110839625-110839625 13:110187278-110187278
4 COL4A1 NM_001845.6(COL4A1):c.1055C>T (p.Pro352Leu)SNV Conflicting interpretations of pathogenicity 39863 rs200786329 13:110853814-110853814 13:110201467-110201467
5 COL4A1 NM_001845.6(COL4A1):c.7C>A (p.Pro3Thr)SNV Uncertain significance 289628 rs751749989 13:110959368-110959368 13:110307021-110307021
6 COL4A1 NM_001845.6(COL4A1):c.2093A>G (p.Lys698Arg)SNV Uncertain significance 447160 rs375318302 13:110835342-110835342 13:110182995-110182995
7 COL4A2 NM_001846.4(COL4A2):c.3368A>G (p.Glu1123Gly)SNV Benign/Likely benign 29629 rs117412802 13:111143601-111143601 13:110491254-110491254
8 COL4A2 NM_001846.4(COL4A2):c.3448C>A (p.Gln1150Lys)SNV Benign/Likely benign 29630 rs62621875 13:111143681-111143681 13:110491334-110491334
9 COL4A2 NM_001846.4(COL4A2):c.5068G>A (p.Ala1690Thr)SNV Benign/Likely benign 29631 rs201105747 13:111164467-111164467 13:110512120-110512120

UniProtKB/Swiss-Prot genetic disease variations for Hemorrhage, Intracerebral:

73
# Symbol AA change Variation ID SNP ID
1 COL4A1 p.Pro352Leu VAR_073810 rs200786329
2 COL4A1 p.Arg538Gly VAR_073811 rs397514624

Expression for Hemorrhage, Intracerebral

Search GEO for disease gene expression data for Hemorrhage, Intracerebral.

Pathways for Hemorrhage, Intracerebral

GO Terms for Hemorrhage, Intracerebral

Cellular components related to Hemorrhage, Intracerebral according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 PLAT CST3 COL4A2 COL4A1 APP APOE
2 extracellular exosome GO:0070062 9.7 PLAT GSR CST3 COL4A2 APP APOE
3 collagen-containing extracellular matrix GO:0062023 9.67 PLAT COL4A2 COL4A1 APOE
4 extracellular matrix GO:0031012 9.58 COL4A2 COL4A1 APOE
5 extracellular space GO:0005615 9.5 PLAT CST3 COL4A2 COL4A1 APP APOE
6 collagen type IV trimer GO:0005587 9.32 COL4A2 COL4A1
7 endoplasmic reticulum lumen GO:0005788 9.02 CST3 COL4A2 COL4A1 APP APOE

Biological processes related to Hemorrhage, Intracerebral according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.58 APP APOE ACE
2 extracellular matrix organization GO:0030198 9.54 COL4A2 COL4A1 APP
3 cellular protein metabolic process GO:0044267 9.5 CST3 APP APOE
4 negative regulation of proteolysis GO:0045861 9.26 PLAT CST3
5 negative regulation of long-term synaptic potentiation GO:1900272 9.16 APP APOE
6 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 8.96 COL4A2 COL4A1
7 positive regulation of amyloid fibril formation GO:1905908 8.62 APP APOE

Molecular functions related to Hemorrhage, Intracerebral according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 8.62 COL4A2 COL4A1

Sources for Hemorrhage, Intracerebral

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....